Michael Ulz
Stock Analyst at Baird
(4.04)
# 429
Out of 4,959 analysts
101
Total ratings
48.39%
Success rate
14.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $42 → $25 | $6.30 | +296.83% | 7 | Aug 12, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $312 → $405 | $454.38 | -10.87% | 11 | Aug 1, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Overweight | $55 → $62 | $42.69 | +45.23% | 5 | Jul 31, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $5.34 | +368.16% | 12 | May 9, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $105 → $102 | $26.00 | +292.31% | 3 | Apr 24, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $40 → $20 | $3.85 | +419.48% | 2 | Apr 1, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $30 → $22 | $1.62 | +1,258.02% | 6 | Apr 1, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Overweight | $29 | $9.77 | +196.83% | 1 | Mar 10, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $11 → $7 | $8.53 | -17.94% | 7 | Mar 5, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $24 → $20 | $2.69 | +643.49% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $10 | $1.02 | +880.39% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $96 | $49.23 | +95.00% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $52 | $12.58 | +313.35% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $57 | $71.52 | -20.30% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $27 | $21.33 | +26.58% | 4 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.15 | +508.70% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $9.74 | +177.21% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $1.65 | +1,115.81% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.64 | +1,136.26% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.70 | +1,322.27% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $3.00 | - | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $4.58 | +555.02% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $10.19 | +341.61% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $500 | $7.75 | +6,351.61% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $29.78 | +168.64% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $7.61 | +97.11% | 3 | Jul 12, 2017 |
Karyopharm Therapeutics
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $25
Current: $6.30
Upside: +296.83%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Equal-Weight
Price Target: $312 → $405
Current: $454.38
Upside: -10.87%
Ionis Pharmaceuticals
Jul 31, 2025
Upgrades: Overweight
Price Target: $55 → $62
Current: $42.69
Upside: +45.23%
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $5.34
Upside: +368.16%
Viking Therapeutics
Apr 24, 2025
Maintains: Overweight
Price Target: $105 → $102
Current: $26.00
Upside: +292.31%
Kyverna Therapeutics
Apr 1, 2025
Maintains: Overweight
Price Target: $40 → $20
Current: $3.85
Upside: +419.48%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $1.62
Upside: +1,258.02%
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $9.77
Upside: +196.83%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Underweight
Price Target: $11 → $7
Current: $8.53
Upside: -17.94%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $2.69
Upside: +643.49%
Feb 3, 2025
Maintains: Overweight
Price Target: $18 → $10
Current: $1.02
Upside: +880.39%
Jan 28, 2025
Maintains: Overweight
Price Target: $46 → $96
Current: $49.23
Upside: +95.00%
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $12.58
Upside: +313.35%
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $71.52
Upside: -20.30%
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $21.33
Upside: +26.58%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.15
Upside: +508.70%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $9.74
Upside: +177.21%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $1.65
Upside: +1,115.81%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $3.64
Upside: +1,136.26%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.70
Upside: +1,322.27%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $3.00
Upside: -
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $4.58
Upside: +555.02%
Oct 8, 2020
Initiates: Outperform
Price Target: $45
Current: $10.19
Upside: +341.61%
May 28, 2020
Maintains: Outperform
Price Target: $300 → $500
Current: $7.75
Upside: +6,351.61%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $29.78
Upside: +168.64%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $7.61
Upside: +97.11%